PRODUCT FACTS:

Alpha-Wellness Heart Care – 7 contains palmitoleic acid (Omega – 7), a natural fatty acid with broader pharmacological benefits than other omega fatty acids. This Harvard-patented product is ultra-purified from Peruvian anchovy fish oil. In 2011, US Patent identified palmitoleic acid (Omega – 7) as a biomarker for metabolic status and administering palmitoleic acid positively impacts lipid metabolism. Heart Care – 7 also received Canada Health Claim as a source of palmitoleic acid (Omega-7) that helps to reduce C-reactive protein levels, a clinical marker of inflammation in December, 2014.

The product manufacturing plant in Korea adheres to Current Good Manufacturing Practices (cGMP) certified by Korean Food and Drug Administration (KFDA). Heart-Care 7 ingredients is recognised by US FDA as Generally Recognised As Safe (GRAS) to be used as food additive. The product is also rated 5-star in IFOS™ (International Fish Oil Standard) Program, the only third-party testing and certification program for fish oils which sets the world’s highest standards for purity, potency and freshness.

1. Improved Lipid Profile and Inflammatory Markers
2. A randomized, blinded, controlled study was performed on mice genetically engineered to develop arterial plaque and cholesterol deposits. Two groups were studied – a control group that received no palmitoleic acid and those who received palmitoleic acid as part of their diet for 12 weeks. HDL cholesterol levels were tracked during the study and the animals were sacrificed at 12 weeks. Their aortas and aortic roots were examined for the development of plaque and cholesterol deposition development.

 The treated animals showed dramatic reductions in aortic cholesterol deposition versus control. Aortic root cross-sections showed a virtual absence of atheroma formation after treatment with palmitoleic acid. Additionally, treated animals showed an 85% increase in HDL levels.

(Source: Cleveland Clinic Foundation, Cleveland, Ohio, USA, Jan 2009)

220. Human adults with dyslipidemia and evidence of mild systemic inflammation (high-sensitivity C-reactive protein [hs-CRP] between 2 and 5 mg/L) were randomly allocated to receive either 220.5 mg of Heart-Care 7 or a placebo (1000 mg of medium chain triglycerides) once per day for 30 days. Participants were asked to maintain their current diet. Serum lipids and hs-CRP were drawn at baseline and study completion.

At 30 days, the results showed 44%, 15%, and 8% significant reductions in CRP, triglyceride, and LDL respectively, and a 5% significant increase in HDL compared with control. (No. of subjects: 60)

(Bernstein, Adam M., Michael F. Roizen, and Luis Martinez. “Purified palmitoleic acid for the reduction of high-sensitivity C-reactive protein and serum lipids: A double-blinded, randomized, placebo controlled study.” Journal of clinical lipidology 8.6 (2014): 612-617.)

2. Enhanced Insulin Sensitivity and Reduced Liver Inflammation

Genetically modified mice with obese type-2 diabetes and low insulin sensitivity (KK-A^y model) were orally administered with 300 mg/kg of palmitoleic acid, or 300 mg/kg of palmitic acid daily for 4 weeks.

Palmitoleic acid significantly reduced body weight increase, ameliorated the development of hyperglycemia and hypertriglyceridemia, and improved insulin sensitivity. In addition, hepatic characteristics were significantly affected, as weight of the liver and hepatic triglyceride levels were lower in the palmitoleic acid group when compared to the control.

Oil red O staining clearly indicated reduced hepatic lipid accumulation in response to palmitoleic acid. Furthermore, palmitoleic acid suppressing proinflammatory gene in the liver.

(Yang, Zhi-Hong, Hiroko Miyahara, and Akimasa Hatanaka. “Chronic administration of palmitoleic acid reduces insulin resistance and hepatic lipid accumulation in KK-A^y Mice with genetic type 2 diabetes.” Lipids in health and disease 10.1 (2011): 120.)

3. Research Comparative between Heart-Care 7 (palmitoleic acid, PA) and eicosapentaenoic acid (EPA or omega 3) in Serum Triglyceride and Body Weight (BW) Reduction

Clinical Study 1: Treatment group was orally administered 300 mg/kg per day (= 9 mg daily) PA for 4 weeks (Yang et al., 2011)

Clinical Study 2: Treatment group was injected with EPA ethyl ester at 1 g/kg per day (= 45mg daily) EPA for 8 weeks (Zhang et al., 2006)

Results: At 5-fold less dosage and in half the administration time, PA is of greater potency than EPA in reducing serum triglyceride in identical mouse models. PA reduced BW gain by 81% vs control while EPA showed no significant (NS) impact on BW gain against its control.